These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30883316)

  • 1. Why Biosimilars Can Never Be Identical To Originators-and Why They Don't Need To Be.
    Reinke T
    Manag Care; 2019 Jan; 28(1):10-11. PubMed ID: 30883316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA's Approach to Regulating Biosimilars.
    Lemery SJ; Ricci MS; Keegan P; McKee AE; Pazdur R
    Clin Cancer Res; 2017 Apr; 23(8):1882-1885. PubMed ID: 28034906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA's Gottlieb Aims To End Biosimilars Groundhog Day.
    Kirkner RM
    Manag Care; 2019 Jan; 28(1):5-6. PubMed ID: 30883313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current market and regulatory landscape of biosimilars.
    Bhatt V
    Am J Manag Care; 2018 Nov; 24(21 Suppl):S451-S456. PubMed ID: 30452213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study.
    Rupert DJ; Jordan AM; Ziemian MA; Brown RM; Fleming NS; Lefebvre RC
    BioDrugs; 2022 Sep; 36(5):645-655. PubMed ID: 35962911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars: the need, the challenge, the future: the FDA perspective.
    Epstein MS; Ehrenpreis ED; Kulkarni PM;
    Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical considerations for the development of biosimilars in oncology.
    Socinski MA; Curigliano G; Jacobs I; Gumbiner B; MacDonald J; Thomas D
    MAbs; 2015; 7(2):286-93. PubMed ID: 25621390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar names for similar biologics.
    Casadevall N; Felix T; Strober BE; Warnock DG
    BioDrugs; 2014 Oct; 28(5):439-44. PubMed ID: 25001080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars: Key regulatory considerations and similarity assessment tools.
    Kirchhoff CF; Wang XM; Conlon HD; Anderson S; Ryan AM; Bose A
    Biotechnol Bioeng; 2017 Dec; 114(12):2696-2705. PubMed ID: 28842986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic Drugs, Biosimilars, and Barriers to Entry.
    Shepherd JM
    Health Matrix Clevel; 2015; 25():139-61. PubMed ID: 29485844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic Biomarkers Evidentiary Considerations for Biosimilar Development and Approval.
    Strauss DG; Wang YM; Florian J; Zineh I
    Clin Pharmacol Ther; 2023 Jan; 113(1):55-61. PubMed ID: 36178447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar or the Same? Why Biosimilars are not the Solution.
    Diependaele L; Cockbain J; Sterckx S
    J Law Med Ethics; 2018 Sep; 46(3):776-790. PubMed ID: 30336096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of the FDA draft guidance on biosimilars for clinicians: what we know and don't know.
    Li E; Hoffman JM
    J Natl Compr Canc Netw; 2013 Apr; 11(4):368-72. PubMed ID: 23584340
    [No Abstract]   [Full Text] [Related]  

  • 14. Biosimilar biologic drugs: a new frontier in medical care.
    Geynisman DM; De Velasco G; Sewell KL; Jacobs I
    Postgrad Med; 2017 May; 129(4):460-470. PubMed ID: 28343424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption.
    Hair J; Maryon T; Lieneck C
    Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars and the European experience: implications for the United States.
    Megerlin F; Lopert R; Taymor K; Trouvin JH
    Health Aff (Millwood); 2013 Oct; 32(10):1803-10. PubMed ID: 24101072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars for Rheumatoid Arthritis: Don't Count Them Out Quite Yet.
    Rychlick N
    Manag Care; 2018 Jan; 27(1):29. PubMed ID: 29369768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars: biologics that meet patients' needs and healthcare economics.
    McCamish M; Yoon W; McKay J
    Am J Manag Care; 2016 Sep; 22(13 Suppl):S439-S442. PubMed ID: 28719221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars: The US Regulatory Framework.
    Christl LA; Woodcock J; Kozlowski S
    Annu Rev Med; 2017 Jan; 68():243-254. PubMed ID: 27813877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.